Effects of anti-RANKL and anti-PD-1 antibodies on cancer-induced osteolysis in mice
- 26 July 2025
- journal article
- Published by Elsevier in Journal of Oral Biosciences
- Vol. 67 (3) , 100682
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (JP20K18465, JP21K10170)
This publication has 53 references indexed in Scilit:
- Tacrolimus, FK506, promotes bone formation in bone defect mouse modelJournal of Oral Biosciences, 2024
- Bone metastatic mammary tumor cell-derived extracellular vesicles inhibit osteoblast maturation via JNK signalingArchives of Biochemistry and Biophysics, 2023
- Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumptionBone, 2021
- Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastasesJournal of Surgical Oncology, 2014
- RANKL Synthesized by Both Stromal Cells and Cancer Cells Plays a Crucial Role in Osteoclastic Bone Resorption Induced by Oral CancerThe American Journal of Pathology, 2013
- Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasisBone, 2011
- Regulation of osteoblast differentiation by transcription factorsJournal of Cellular Biochemistry, 2006
- Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatiteBone, 2006
- The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosisBone, 2004
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998